Research
Energy balance
Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.
Practitioners can consider cagrilintide-semaglutide as an effective treatment for weight management in this population.
StrongSupportsmedium confidence
Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.
Why this rating
Based on the phase 3a, double-blind, randomized, placebo-controlled trial design.
Source
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Melanie J. Davies et al. · New England Journal of Medicine · 2025
rct · n=1206Cited 78×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →